Avalo Therapeutics (AVTX) Cash from Investing Activities (2016 - 2026)

Avalo Therapeutics posted quarterly Cash from Investing Activities of $25.5 million for Q1 2026, up 962.27% on a QoQ basis from $2.4 million in Q4 2025.

Avalo Therapeutics (AVTX) has 11 years of Cash from Investing Activities data on file, last reported at $25.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Investing Activities changed N/A year-over-year to $25.5 million; the trailing twelve-month figure through Mar 2026 stood at -$56.2 million (changed N/A YoY), and the FY2025 full-year result was -$81.7 million, down 23055.06% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at $25.5 million, up from $2.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $25.5 million in Q1 2026 and bottomed at -$70.9 million in Q2 2025.
  • The 5-year median for Cash from Investing Activities is -$47500.0 (2022), against an average of -$7.0 million.
  • The widest annual swing landed in 2022, when Cash from Investing Activities jumped 51.85%; it then surged 367.67% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$39000.0 in 2022, then tumbled by 241.03% to -$133000.0 in 2023, then soared by 367.67% to $356000.0 in 2024, then soared by 574.44% to $2.4 million in 2025, then soared by 962.27% to $25.5 million in 2026.
  • The last three Cash from Investing Activities figures came in at $25.5 million (Q1 2026), $2.4 million (Q4 2025), and -$13.3 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.89 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 638.50 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -431.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -428.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -25.54 Mn
10 Avalo Therapeutics 317.29 Mn 317.29 Mn - 25.51 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 25.51 Mn
Mar 31, 2026 25.51 Mn
Dec 31, 2025 2.40 Mn
Dec 31, 2025 2.40 Mn
Sep 30, 2025 -13.26 Mn
Sep 30, 2025 -13.26 Mn
Jun 30, 2025 -70.86 Mn
Jun 30, 2025 -70.86 Mn
Mar 31, 2024 356,000.00
Mar 31, 2024 356,000.00
Mar 31, 2023 -133,000.00
Mar 31, 2023 -133,000.00
Sep 30, 2022 -39,000.00
Sep 30, 2022 -39,000.00
Jun 30, 2022 -56,000.00
Jun 30, 2022 -56,000.00
Dec 31, 2021 -11,000.00
Dec 31, 2021 -11,000.00
Sep 30, 2021 -81,000.00
Sep 30, 2021 -81,000.00
Mar 31, 2021 -21,000.00
Mar 31, 2021 -21,000.00
Dec 31, 2020 -391,000.00
Dec 31, 2020 -391,000.00
Sep 30, 2020 -63,000.00
Sep 30, 2020 -63,000.00
Jun 30, 2020 12.84 Mn
Jun 30, 2020 12.84 Mn
Mar 31, 2020 -1.25 Mn
Mar 31, 2020 -1.25 Mn
Dec 31, 2019 -180,991.00
Dec 31, 2019 -180,991.00
Sep 30, 2019 -5,085.00
Sep 30, 2019 -5,085.00
Jun 30, 2019 -90,957.00
Jun 30, 2019 -90,957.00
Mar 31, 2019 -165,969.00
Mar 31, 2019 -165,969.00
Dec 31, 2018 -499,357.00
Dec 31, 2018 -499,357.00
Sep 30, 2018 1.39 Mn
Sep 30, 2018 1.39 Mn
Jun 30, 2018 -6,707.00
Jun 30, 2018 -6,707.00
Mar 31, 2018 -19,225.00
Mar 31, 2018 -19,225.00
Dec 31, 2017 -18.90 Mn
Dec 31, 2017 -18.90 Mn
Sep 30, 2017 -6,189.00
Sep 30, 2017 -6,189.00
Mar 31, 2017 -1,801.00
Mar 31, 2017 -1,801.00
Dec 31, 2016 -9,237.00
Dec 31, 2016 -9,237.00
Sep 30, 2016 -6,489.00
Sep 30, 2016 -6,489.00
Jun 30, 2016 -10,259.00
Jun 30, 2016 -10,259.00
Mar 31, 2016 -8,898.00
Mar 31, 2016 -8,898.00